Printer Friendly

ALPHA-BETA TECHNOLOGY BEGINS BETAFECTIN PHASE II CLINICAL TRIALS

 ALPHA-BETA TECHNOLOGY BEGINS BETAFECTIN PHASE II CLINICAL TRIALS
 WORCESTER, Mass., Aug. 13 /PRNewswire/ -- Alpha-Beta Technology, Inc. announced today that the company has started Phase II clinical trials with Betafectin(tm), its patented carbohydrate-based compound for the prevention and treatment of infections in immune compromised patients. The studies, in patients undergoing major chest or abdominal surgery, are the first of several planned Phase II trials in a number of clinical conditions.
 "The trials are designed to provide preliminary data on the effectiveness of Betafectin in decreasing the incidence and severity of infections following major surgery as well as additional information on product safety and tolerance," said Dr. Spiros Jamas, Alpha-Beta's president and chief executive officer. "The studies follow Phase I trials in healthy volunteers, completed earlier this year, in which Betafectin proved safe and demonstrated promising indications of biological activity."
 The Phase II trials, which are randomized, open label studies, will compare the effect of multiple doses of Betafectin, administered just prior to and after surgery, with an untreated control group. Both the Betafectin and control groups will receive conventional prophylactic treatment with antibiotics. Even with the use of antibiotics the post- surgical infection rate in these patients is estimated to exceed 25 percent. Post-surgical infections in this patient population frequently lead to increased hospital stays and can be life-threatening.
 The trials are being conducted at the University of Massachusetts Medical Center in Worcester and Deaconess Hospital in Boston.
 Betafectin is an engineered carbohydrate polymer that targets a protein on infection-fighting white blood cells called the B-glucan receptor. The resulting carbohydrate-receptor interaction primes the specific immune responses that increase the body's defenses against pathogens without undesirable effects such as inflammation.
 Alpha-Beta Technology, Inc. is developing patentable carbohydrate- based products for the health care industry through the application of carbohydrate engineering. The company's major products in development include Betafectin(tm) for the treatment and prevention of infections related to surgery and chemotherapy; Cholestran(tm) for the treatment and prevention of cardiovascular disease; and Fibercel(tm), a fat substitute. Alpha-Beta's headquarters, laboratory and pilot production facilities are located in Worcester.
 -0- 8/13/92
 /CONTACT: Spiros Jamas, president and CEO of Alpha-Beta Technology 508-798-6900; or Robert Gottlieb of Feinstein Partners, 617-577-8110, for Alpha-Beta Technology/ CO: Alpha-Beta Technology, Inc. ST: Massachusetts IN: MTC SU:


CH -- NE005 -- 9457 08/13/92 08:28 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 13, 1992
Words:389
Previous Article:GATEWAY 2000 BUCKS THE PC INDUSTRY TREND: SECOND-QUARTER REVENUE UP, EARNINGS UP
Next Article:APPLE SHIPS UPDATES TO ITS POWERFUL DEVELOPMENT TOOLS SUITE
Topics:


Related Articles
BETAFECTIN(R) PGG-GLUCAN PHASE II CLINICAL TRIAL RESULTS PRESENTED AT SURGICAL INFECTION SOCIETY MEETING
ALPHA-BETA TECHNOLOGY COMPLETES HEALTHY VOLUNTEER STUDY FOR BETAFECTIN PGG-GLUCAN; PRODUCT ON SCHEDULE FOR PIVOTAL TRIAL BY YEAR-END
ALPHA-BETA TECHNOLOGY BEGINS PHASE III CLINICAL TRIAL FOR BETAFECTIN PGG-GLUCAN FOR THE PREVENTION OF POST-SURGICAL INFECTION
ALPHA-BETA TECHNOLOGY, INC. FILES IND TO BEGIN NEW CLINICAL PROGRAM FOR BETAFECTIN PGG-GLUCAN AS CHEMOTHERAPY ADJUNCT
ALPHA-BETA TECHNOLOGY, INC. BEGINS CLINICAL PROGRAM TO DEVELOP BETAFECTIN PGG-GLUCAN AS CHEMOTHERAPY ADJUNCT
Alpha-Beta Technology Announces Phase II Clinical Trial for Betafectin PGG-Glucan in Patients Undergoing Surgery for Inflammatory Bowel Disease (IBD)
Alpha-Beta Technology Announces Data Safety Monitoring Board Review of Phase III Data
Alpha-Beta Technology, Inc. Provides Update on Betafectin PGG-glucan Clinical Program at the 15th Annual Hambrecht & Quist Healthcare Conference
Alpha-Beta Announces Preliminary Analysis of Betafectin(R) Phase III Clinical Trial
Alpha-Beta Agrees with FDA on Confirmatory Phase III Trial of Betafectin(R) PGG-glucan in Non-Colorectal G-I Surgery Patients

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters